Stock fact sheet · data as of
Cencora, Inc. (COR): fair value, margin of safety and Wheel Score
Healthcare · Medical - Distribution · United States · High Growth
Is COR undervalued?
At 341.41 (close of 16 Oct 2026), COR trades 15% under the GLS average fair value of 400.52. 5 of the 9 models that produced a value land above the price. A discount of this size counts as a positive margin of safety in every GLS screen; whether it is enough depends on the rest of the picture - the health score, the moat and the option premium below.
The 9 models disagree widely: DDM gives 35.31 while Payback Time gives 832.38. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files COR under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for COR
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 517.97 | +52% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 69.50 | -80% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 450.34 | +32% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 172.53 | -49% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 831.96 | +144% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 543.67 | +59% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 832.38 | +144% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | 35.31 | -90% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | 151.00 | -56% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -118.45 | -135% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 358.14 | +5% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
On financial health COR scores 7/9 (Piotroski): most of the nine tests - positive earnings and cash flow, falling debt, rising margins and turnover - are passed, which is the kind of balance sheet a wheel trader is happy to be assigned. The GLS Moat score is 5.6 out of 10: a ten-year record that is consistent in some of the metrics the score tracks (revenue, earnings, margins, cash flow, returns on capital) and patchy in others.
Returns on capital are high - ROIC 12.7%, ROE 103.1%, ROA 2.0% - with debt at 7.13 times equity and a free-cash-flow yield of 6.2%. Debt of 7.13 times equity is on the high side for the sector and is worth checking against the cash flow before treating the stock as a long-term hold.
The dividend yield is 0.70% with a payout ratio of 18% - a small yield that leaves most of the earnings in the business. Revenue comes mainly from U.S. Healthcare Solutions 88%, International Healthcare Solutions 9%, Other 3% (quarter Q3 FY2026).
Institutional ownership scores 10/10, insider activity 3/10 and Congressional trading 6/10 on the GLS smart-money scales; the last recorded Congressional buy was on 4 Sep 2026.
| Piotroski F-score | 7 / 9 | ROIC | 12.7% |
|---|---|---|---|
| GLS Moat | 5.6 / 10 | ROE | 103.1% |
| Debt / equity | 7.13 | ROA | 2.0% |
| Free-cash-flow yield | 6.2% | Payout ratio | 18% |
| Institutions | 10 / 10 | Insiders · Congress | 3 · 6 / 10 |
Wheel Score 82: Prime
COR scores 82 out of 100 on the Wheel Score, in the Prime band (80 and above), which fewer than one stock in twenty reaches on any night. The score blends five things a wheel trader checks before selling a cash-secured put: the margin of safety (Value, 19/25), Piotroski health (16/20), the GLS moat (8/15), the option premium on offer (20/20) and how easily the stock trades (19/20).
Implied volatility is 36% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is 15,009 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 1.6M shares a day on a market cap of $65.2B, with a beta of 0.58 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 19 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 19 / 25 | 15% margin of safety | |
| Health | 16 / 20 | Piotroski 7/9 | |
| Moat | 8 / 15 | moat 5.6/10 | |
| Premium | 20 / 20 | implied volatility 36% | |
| Stability | 19 / 20 | 1.6M shares/day, $65.2B cap, beta 0.58 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 4 Nov 2026 (before the open), 19 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Distribution
The 12 companies below are the closest to Cencora, Inc. by market cap within the Medical - Distribution industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| CAH Cardinal Health, Inc. | 253.71 | 343.24 | +26% | 88Prime | $58.7B |
| MCK McKesson Corporation | 998.64 | 833.66 | -20% | 65Good | $116.4B |
| HSIC Henry Schein, Inc. | 86.99 | 63.41 | -37% | 56Fair | $9.7B |
| AHG Akso Health Group | 1.35 | - | - | 29No options | $1.2B |
| YI 111, Inc. | 3.11 | - | - | 26No options | $27M |
| ACH Accendra Health, Inc. | 0.2615 | - | - | 36Weak | $20M |
| EXHI Exlites Holdings International, Inc. | 0.4500 | - | - | 26No options | $20M |
| MEDS DataMEDS AI, Inc. | 2.85 | - | - | 24No options | $7M |
| AIXN AiXin Life International, Inc. | 0.2600 | - | - | 27No options | $6M |
| PDRX PD-Rx Pharmaceuticals, Inc. | 3.10 | 6.80 | +54% | 29No options | $5M |
| HKPD Cellyan Biotechnology Co., Ltd | 0.1099 | 0.3564 | +69% | 39No options | $5M |
| RDGT Ridgetech, Inc. | 0.8402 | 312.83 | +100% | 39No options | $755K |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about COR
Is COR undervalued right now?
By the GLS models, moderately: at 341.41 the stock trades 15% below the average fair value of 400.52 (data as of 16 Oct 2026).
What is the Wheel Score of COR and what does it mean?
COR scores 82 out of 100 (Prime). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for COR?
400.52 per share as of 16 Oct 2026 - the simple average of the 9 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Cencora, Inc. report earnings next?
The next earnings report is due on 4 Nov 2026 (before the open), 19 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does COR have listed options, and how liquid are they?
Yes. The nightly snapshot found 730 listed contracts with 15,009 open interest across all expiries and implied volatility of 36% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.